IP Library Granted Patent US 8,214,030
Granted Patent B2
US 8,214,030 · App. 11/733,700 · Granted Jul 3, 2012

Iontophoresis apparatus and method

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,214,030
App. No.
11/733,700
Granted
Jul 3, 2012
Kind
B2
Abstract

An iontophoresis apparatus and method is disclosed that is suited to deliver a plurality of treatment methods such as, but not limited to, body site conductivity enhancement followed by low voltage iontophoresis.

Claims (39)

1. An apparatus for applying an iontophoretic transdermal process to a body site comprising:

a treatment delivery unit, including first and second power supplies, configured to:

receive a selection of one of a plurality of treatment modes; and deliver:

using the first power supply but not the second power supply, the selected one of the plurality of treatment modes to the body site;

using the second power supply, after using the first power supply, a low voltage iontophoretic transdermal patch treatment to the body site.

2. The apparatus of claim 1 wherein delivering a selected one of the plurality of treatment modes to the body site comprises delivering about 2 milliAmps when a low current mode is selected, delivering about 3 milliAmps when a medium current mode is selected, and delivering about 4 milliAmps when a high current mode is selected.

3. The apparatus of claim 1 wherein delivering a selected one of the plurality of treatment modes to the body site comprises delivering about 0.5 milliAmps when a low current mode is selected, delivering about 1 milliAmp when a medium current mode is selected, and delivering about 1.5 milliAmps when a high current mode is selected.

4. The apparatus of claim 1 further comprising at least one of a thumbwheel, dial or membrane switch operable to adjust the treatment delivered when one of the plurality of treatment modes is selected.

5. The apparatus of claim 1 wherein the treatment delivery unit comprises a controller mounted to an iontophoretic patch.

6. The apparatus of claim 1 wherein the treatment delivery unit comprises a controller operatively attached to a connector integral to an iontophoretic patch.

7. The apparatus of claim 1 wherein the plurality of treatment modes includes a body site conductivity enhancement mode.

8. The apparatus of claim 7 wherein delivering the body site conductivity enhancement mode comprises applying a current of about 3 milliAmps to the body site.

9. The apparatus of claim 7 wherein delivering the body site conductivity enhancement mode comprises applying a current in the range of about 0.1 to 4 milliAmps to the body site.

10. The apparatus of claim 7 wherein delivering the body site conductivity enhancement mode comprises applying a current density of 0.53 milliAmp/centimeters 2 , or less, to the body site.

11. The apparatus of claim 1 wherein the second power supply is integral to the iontophoretic patch.

12. The apparatus of claim 7 further comprising an indicator to provide a warning if the electrical conductivity of the body site has not been adequately enhanced at the completion of the delivery of the body site conductivity enhancement mode.

13. The apparatus of claim 1 wherein the second power supply is a disposable power source.

14. An apparatus comprising an iontophoresis controller having a housing keyed to a connector mounted to an iontophoretic patch, wherein:

the housing is removably engageable with the iontophoretic patch via the connector, and

the iontophoretic patch is capable of delivering a first iontophoresis treatment when the controller is engaged and a second iontophoresis treatment when the controller is disengaged.

15. The apparatus of claim 14 wherein the keying is based on a medicine to be applied.

16. The apparatus of claim 14 wherein the iontophoresis controller includes a first power supply.

17. The apparatus of claim 16 wherein the first iontophoresis treatment is provided using the first power supply.

18. The apparatus of claim 14 wherein a second power supply included in the iontophoretic patch is bypassed during the first iontophoresis treatment.

19. The apparatus of claim 16 wherein the first power supply is a rechargeable battery.

20. The apparatus of claim 14 wherein the second iontophoretic treatment is mechanically triggered by disengaging the controller from the iontophoretic patch.

21. The apparatus of claim 18 , wherein contact between the iontophoretic patch and the second power supply is deflected when the controller is engaged.

22. The apparatus of claim 14 wherein the second iontophoretic treatment is electrically triggered by disengaging the controller from the iontophoretic patch.

23. The apparatus of claim 22 , further comprising a transistor switch for electrically triggering the second iontophoretic treatment by disengaging the controller from the iontophoretic patch.

24. The apparatus of claim 14 wherein the second iontophoretic treatment is triggered by the completion of the first iontophoresis treatment.

25. The apparatus of claim 14 wherein the iontophoretic patch includes a disposable power supply.

26. The apparatus of claim 14 , wherein the housing is keyed to the connector via a plurality of electrical contact pins.

27. The apparatus of claim 26 wherein the first iontophoresis treatment is based on the keying.

28. The apparatus of claim 26 wherein the keying is based on a voltage level to be used in the first iontophoretic treatment.

29. The apparatus of claim 26 , wherein the keying is based on the position of one or more jumpers included in the connector.

30. The apparatus of claim 14 , wherein the connector includes one or more electrical contact nodes which identify the iontophoretic patch to the controller.

31. The apparatus of claim 7 , wherein delivering the body site conductivity enhancement mode comprises applying a current to the body site over a time period of between about 1.2 minutes and about 3 minutes.

32. The apparatus of claim 1 wherein the first and second power supplies are selectively operable.

33. The apparatus of claim 6 , wherein the controller is operatively attached to the iontophoretic patch via a plurality of electrical contact pins.

Assignments (15)
MERGER Recorded Nov 19, 2025
From: ENCORE MEDICAL ASSET CORPORATION
To: DJO, LLC
Reel/Frame 072961/0169 →
SECURITY INTEREST Recorded Jan 3, 2024
From: DJO, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 066186/0659 →
RELEASE OF SECURITY INTEREST Recorded Mar 21, 2019
From: WELLS FARGO BANK, NATIONAL ASSOCIATION AS COLLATERAL AGENT
To: DJO, LLC; ENCORE MEDICAL, L.P.; EMPI, INC.; ENCORE MEDICAL ASSET CORPORATION; RIKCO INTERNATIONAL, LLC
Reel/Frame 048672/0661 →
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2019
From: MACQUARIE US TRADING LLC AS COLLATERAL AGENT
To: DJO, LLC; ENCORE MEDICAL, L.P.; EMPI, INC.; ENCORE MEDICAL ASSET CORPORATION; RIKCO INTERNATIONAL, LLC
Reel/Frame 048655/0067 →
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2019
From: THE BANK OF NEW YORK MELLON AS SECOND LIEN AGENT
To: DJO, LLC; ENCORE MEDICAL, L.P.; EMPI, INC.; ENCORE MEDICAL ASSET CORPORATION; RIKCO INTERNATIONAL, LLC
Reel/Frame 050129/0262 →
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2019
From: THE BANK OF NEW YORK MELLON AS THIRD LIEN AGENT
To: DJO, LLC; ENCORE MEDICAL, L.P.; EMPI, INC.; ENCORE MEDICAL ASSET CORPORATION; RIKCO INTERNATIONAL, LLC
Reel/Frame 048608/0932 →
RELEASE BY SECURED PARTY Recorded Jan 16, 2019
From: BANK OF AMERICA, N.A.
To: REABLE THERAPEUTICS HOLDINGS LLC; REABLE THERAPEUTICS FINANCE LLC
Reel/Frame 048080/0952 →
SECURITY AGREEMENT Recorded May 18, 2015
From: DJO, LLC; EMPI, INC.; ENCORE MEDICAL ASSET CORPORATION; ENCORE MEDICAL, L.P.; RIKCO INTERNATIONAL, LLC
To: THE BANK OF NEW YORK MELLON, AS SECOND LIEN AGENT
Reel/Frame 035707/0454 →
RELEASE OF SECURITY INTEREST Recorded May 18, 2015
From: CREDIT SUISSE AG, AS COLLATERAL AGENT
To: DJO, LLC; ENCORE MEDICAL ASSET CORPORATION; RIKCO INTERNATIONAL, LLC
Reel/Frame 035706/0497 →
RELEASE OF SECURITY INTEREST Recorded May 18, 2015
From: THE BANK OF NEW YORK MELLON, AS SECOND LIEN AGENT
To: DJO, LLC; ENCORE MEDICAL ASSET CORPORATION; RIKCO INTERNATIONAL, LLC; EMPI, INC.
Reel/Frame 035706/0457 →
SECURITY AGREEMENT Recorded May 18, 2015
From: DJO, LLC; EMPI, INC.; ENCORE MEDICAL ASSET CORPORATION; ENCORE MEDICAL, L.P.; RIKCO INTERNATIONAL, LLC
To: MACQUARIE US TRADING LLC, AS COLLATERAL AGENT
Reel/Frame 035707/0398 →
SECURITY AGREEMENT Recorded May 18, 2015
From: DJO, LLC; EMPI, INC.; ENCORE MEDICAL ASSET CORPORATION; ENCORE MEDICAL, L.P.; RIKCO INTERNATIONAL, LLC
To: THE BANK OF NEW YORK MELLON, AS THIRD LIEN AGENT
Reel/Frame 035707/0498 →
SECURITY INTEREST Recorded May 7, 2015
From: DJO, LLC; EMPI, INC.; ENCORE MEDICAL ASSET CORPORATION; ENCORE MEDICAL, L.P.; RIKCO INTERNATIONAL, LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS THE COLLATERAL AGENT
Reel/Frame 035614/0001 →
CHANGE OF NAME Recorded Mar 24, 2014
From: IOMED, INC.
To: IOMED, LLC
Reel/Frame 032536/0225 →
SECURITY AGREEMENT Recorded Apr 20, 2012
From: DJO, LLC; EMPI, INC.; ENCORE MEDICAL ASSET CORPORATION; RICKO INTERNATIONAL, LLC
To: THE BANK OF NEW YORK MELLON, AS SECOND LIEN AGENT
Reel/Frame 028078/0320 →